

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC. and APOTEX CORP.

Petitioners

v.

ABRAXIS BIOSCIENCE, LLC

Patent Owner

U.S. Patent No. 7,923,536
Filed: April 12, 2010
Issued: April 12, 2011
Inventor: Neil P. Desai, et al.

TITLE: COMPOSITIONS AND METHODS OF
DELIVERY OF PHARMACOLOGICAL AGENTS

Inter Partes Review No.: IPR2018-00153

**PETITIONERS' MOTION FOR JOINDER PURSUANT
TO 35 U.S.C. § 315(c) AND 37 C.F.R. §§ 42.22 & 42.122(b)**

TABLE OF CONTENTS

I. STATEMENT OF THE PRECISE RELIEF REQUESTED 1

II. STATEMENT OF MATERIAL FACTS 2

III. STATEMENT OF REASONS FOR RELIEF REQUESTED 3

 A. Joinder Is Appropriate Because It Will Expedite Resolution of the
 Proceeding 5

 1. Substantively Identical Petitions 5

 2. Consolidated Filings and Discovery 6

 B. No New Grounds of Unpatentability 6

 C. No Impact on IPR Trial Schedule 7

 D. Briefing and Discovery Will Be Streamlined 7

 E. Joinder Will Not Prejudice Abraxis or Actavis 7

 F. Expedited Briefing will Ensure Efficient Administration of the Joint
 Proceeding 8

IV. PROPOSED ORDER 8

V. CONCLUSION 9

TABLE OF AUTHORITIES

Page(s)

Cases

Abraxis BioScience, LLC et al., v. Actavis LLC,
No. 2:16-cv-01925 (D.N.J).....2

Advanced Micro Devices Inc. v. Zond LLC, Paper No. 12,
IPR2014-01042 (November 7, 2014) 1

Amneal Pharm., LLC v. Yeda Res. & Dev. Co., Ltd., Paper No. 9,
IPR2015-01976 (Dec. 28, 2015)..... 1

Dell, Inc. v. Network-1 Security Solutions, Inc.,
IPR2013-00385, Paper No. 17, Slip Op. (July 29, 2013).....4

Kyocera Corp. et al. v. Softview LLC, Paper No. 15, IPR2013-00004,
Apr. 24, 2013 1

Statutes

35 U.S.C. § 315(c) 1, 3

35 U.S.C. § 316(b) 4

Other Authorities

37 C.F.R. § 42.1(b) 5, 8

37 C.F.R. § 42.22 1, 2, 3

37 C.F.R. § 42.122(b) 1, 2, 3

157 CONG. REC. S1376 (daily ed. Mar. 8, 2011)
(statement of Sen. Kyl).....5

..

I. STATEMENT OF THE PRECISE RELIEF REQUESTED

Pursuant to 35 U.S.C. § 315(c) and 37 C.F.R. §§ 42.22 & 42.122(b), Petitioners Apotex Inc. and Apotex Corp. (“Apotex”) request institution of an *inter partes* review concerning U.S. Patent No. 7,923,536 (“the ’536 patent”) and move for joinder with the *inter partes* review concerning the same patent, *Actavis LLC v. Abraxis BioScience, LLC*, IPR2017-01103 (the “Actavis IPR”) that was instituted on October 10, 2017.

In view of the Board’s Representative Order outlining issues to be addressed in a motion for joinder (*Kyocera Corp. et al. v. Softview LLC*, Paper No. 15, IPR2013-00004, Apr. 24, 2013), Petitioners submit that: (1) joinder is appropriate because it will promote efficient resolution of the proceedings without prejudice to the prior petitioner and patent owner, Actavis LLC (“Actavis”) and Abraxis BioScience, LLC (“Abraxis”), respectively; (2) Petitioners’ IPR petition (“Apotex Petition”) does not raise new grounds of unpatentability over those instituted by the Board in the Actavis IPR; (3) joinder would not affect the pending schedule in the Actavis IPR; and (4) Petitioners and Actavis agree to submit consolidated filings to minimize the burden and the impact on the schedule. *See, e.g., Advanced Micro Devices Inc. v. Zond LLC*, Paper No. 12, IPR2014-01042 (Nov. 7, 2014) and *Amneal Pharm., LLC v. Yeda Res. & Dev. Co., Ltd.*, Paper No. 9, IPR2015-01976 (Dec. 28, 2015) (granting motions for joinder under similar circumstances). Petitioners have

also agreed to work with Actavis and take an “understudy” role in the joint IPR so long as Actavis does not settle and/or dismiss the Actavis IPR.

This Motion for Joinder is timely under 37 C.F.R. §§ 42.22 & 42.122(b) because it is submitted within one month from the October 10, 2017 date the Board instituted the Actavis IPR. Actavis IPR, Paper No. 7.

II. STATEMENT OF MATERIAL FACTS

1. On April 6, 2016, Abraxis filed a complaint against Actavis asserting infringement of the ’536 patent and related U.S. Patent Nos. 8,138,229 and 7,820,788. *Abraxis BioScience, LLC et al., v. Actavis LLC*, No. 2:16-cv-01925 (D.N.J).

2. On April 4, 2017, Actavis filed a petition for *inter partes* review of the ’536 patent, alleging unpatentability of all claims on anticipation and obviousness grounds. Actavis IPR, Paper No. 2.

3. On July 12, 2017, Abraxis filed a Preliminary Patent Owner’s response. *Id.*, Paper No. 6.

4. On October 10, 2017, the Board instituted trial on the grounds of unpatentability raised by Actavis for Claims 1-16 of the ’536 patent. *Id.*, Paper No. 7.

5. On November 9, 2017, Petitioners filed the Apotex Petition and Motion for Joinder within one month of the Actavis IPR October 10, 2017 institution date.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.